Event

Separate registration required.

In this course, participants will be guided through a hands-on analysis of real-world data to develop decision-grade real-world evidence (RWE) that could be used to support an indication expansion. The first section of the course focuses on what makes RWE “decision-grade.” We will review the most recent RWE frameworks and guidelines set by regulatory agencies and professional organizations, and we will examine case studies in which these guidelines were used in regulatory and HTA approval. The second half of the course is an active workshop where participants will use principles from the first half of the course to execute a decision-grade RWE study. Participants will be guided step-by-step in using a software platform that will enable them to work within a longitudinal US insurance claims database with anonymized patients. After the study has been executed, we will discuss how these results could be communicated to decision makers. Participants should come with a laptop with Google ChromeTM installed.

PREREQUISITE: Students are expected to be familiar with relevant concepts and methodologies for analyzing real-world data, but this course does not require specific programming skills.

Principal Consultant, Epidemiology and Real-World Evidence

Optum

Boston, MA, USA

Co-Founder & Chief Scientific Officer

Aetion, Inc.

New York, NY, USA

Associate Professor of Medicine

Division of Pharmacoepidemiology and Pharmacoeconomics

Department of Medicine, Brigham and Women’s Hospital

Harvard Medical School

Boston, MA, USA